Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma

Immunology

Volumn 132, Issue 1, 2011, Pages 39-48

  Atai, Nadia A ^a,b,e   Bansal, Manju ^b,e   Lo, Cheungh ^b,e   Bosman, Joost ^a   Tigchelaar, Wikky ^a   Bosch, Klazien S ^a   Jonker, Ard ^a   De Witt Hamer, Philip C ^c   Troost, Dirk ^a   McCulloch, Christopher A ^b,e   Everts, Vincent ^d   Van Noorden, Cornelis J F ^a   Sodek, Jaro ^b,e  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF TORONTO   (Canada)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Glioblastoma; Macrophage; Migration; Neutrophil; Osteopontin; RGD

Indexed keywords

OSTEOPONTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BLADDER CARCINOMA; BREAST CARCINOMA; CANCER PATIENT; CELL INFILTRATION; COLON CARCINOMA; COMPUTER MODEL; CONTROLLED STUDY; GENE EXPRESSION; GLIOBLASTOMA; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LEIOMYOSARCOMA; LUNG CANCER; MACROPHAGE; MELANOMA; MICROARRAY ANALYSIS; MOUSE; NEUTROPHIL; NONHUMAN; OLIGODENDROGLIA; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEMINOMA; STOMACH CARCINOMA; THYROID CARCINOMA; UPREGULATION;

ANIMALS; CELL MOVEMENT; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MICE; MUTATION; NEUTROPHILS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOPONTIN; UP-REGULATION;

EID: 78649990580     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2010.03335.x     Document Type: Article

References (104)

1. Sodek J, Ganss B, Mckee MD. Osteopontin. Crit Rev Oral Biol Med 2000; 11:279-303.
2. Sodek J, Zhu B, Huynth MH, Brown TJ, Ringuette M. Novel functions of the matricellular proteins osteopontin and osteonectin/SPARC. Connect Tissue Res 2002; 43:308-19.
3. Denhardt DT, Giachelli CM, Rittling SR. Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol 2001; 41:723-49.
4. Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 2008; 27:103-18.
5. Ramaiah SK, Rittling S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci 2008; 103:4-13.
6. Alstergren P, Zhu B, Glogauer M, Mak TW, Ellen RP, Sodek J. Polarization and directed migration of murine neutrophils is dependent on cell surface expression of CD44. Cell Immunol 2004; 231:146-57.
7. Apte UM, Mcree R, Ramaiah SK. Osteopontin induction: possible mechanism behind hepatic neutrophil infiltration during alcoholic steatohepatitis. Hepatology 2003; 38:266A.
8. Ashkar S, Salih E, Gerstenfeld LC, Glimcher MJ. Localization and identification of a chemotactic domain on osteopontin. A possible role for osteopontin and its peptides in bone healing. J Bone Min Res 1996; 11:M442.
9. Bennett JS, Berger BW, Billings PC. The structure and function of platelet integrins. J Thromb Haemost 2009; 7(Suppl. 1):200-5.
10. Ding Q, Stewart J, Prince CW, Chang PL, Trikha M, Han XS, Grammer JR, Gladson CL. Promotion of malignant astrocytoma cell migration by osteopontin expressed in the normal brain: differences in integrin signaling during cell adhesion to osteopontin versus vitronectin. Cancer Res 2002; 62:5336-43.
11. Ramaiah SK, Rittling S. Role of osteopontin in regulating hepatic inflammatory responses and toxic liver injury. Expert Opin Drug Metab Toxicol 2007; 3:519-26.
12. Ramaiah SK, Jaeschke H. Role of neutrophils in the pathogenesis of acute inflammatory liver injury. Toxicol Pathol 2007; 35:757-66.
13. Shijubo N, Uede T, Kon S, Nagata M, Abe S. Vascular endothelial growth factor and osteopontin in tumor biology. Crit Rev Oncol 2000; 11:135-46.
14. Chakraborty G, Jain S, Patil TV, Kundu GC. Down-regulation of osteopontin attenuates breast tumour progression in vivo. J Cell Mol Med 2008; 12:2305-18.
15. Lamour V, Le MM, Lefranc F et al. Selective osteopontin knockdown exerts anti-tumoral activity in a human glioblastoma model. Int J Cancer 2009; 126:1797-805.
16. Shevde LA, Samant RS, Paik JC, Metge BJ, Chambers AF, Casey G, Frost AR, Welch DR. Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma MDA-MB-435.. Clin Exp Metastasis 2006; 23:123-33.
17. Wai PY, Mi Z, Guo H et al. Osteopontin silencing by small interfering RNA suppresses in vitro and in vitro CT26 murine colon adenocarcinoma metastasis. Carcinogenesis 2005; 26:741-51.
18. Zhao J, Dong L, Liu B et al. Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology 2008; 135:956-68.
19. Zohar R, Zhu B, Liu P, Sodek J, McCulloch CA. Increased cell death in osteopontin-deficient cardiac fibroblasts occurs by a caspase-3-independent pathway. Am J Physiol Heart Circ Physiol 2004; 287:H1730-9.
20. Koh A, Da Silva AP, Bansal AK et al. Role of osteopontin in neutrophil function. Immunology 2007; 122:466-75.
21. Apte UM, Banerjee A, Mcree R, Wellberg E, Ramaiah SK. Role of osteopontin in hepatic neutrophil infiltration during alcoholic steatohepatitis. Toxicol Appl Pharmacol 2005; 207:25-38.
22. Fossati G, Ricevuti G, Edwards SW, Walker C, Dalton A, Rossi ML. Neutrophil infiltration into human gliomas. Acta Neuropathol 1999; 98:349-54.
23. McDonald B, Spicer J, Giannais B, Fallavollita L, Brodt P, Ferri LE. Systemic inflammation increases cancer cell adhesion to hepatic sinusoids by neutrophil mediated mechanisms. Int J Cancer 2009; 125:1298-305.
24. Zhu B, Suzuki K, Goldberg HA, Rittling SR, Denhardt DT, McCulloch CA, Sodek J. Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: evidence of a role for an intracellular form of osteopontin. J Cell Physiol 2004; 198:155-67.
25. Bramwell VHC, Doig GS, Tuck AB et al. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 2006; 12:3337-43.
26. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF, Harris JF. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997; 3:605-11.
27. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994; 145:610-23.
28. Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 2002; 95:506-12.
29. Ramankulov A, Lein M, Kristiansen G, Loening SA, Jung K. Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 2007; 67:330-40.
30. Ye QH, Qin LX, Forgues M et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003; 9:416-23.
31. Le QT, Denko NC, Giaccia AJ. Hypoxic gene expression and metastasis. Cancer Metastasis Rev 2004; 23:293-310.
32. Matusan-Ilijas K, Behrem S, Jonjic N, Zarkovic K, Lucin K. Osteopontin expression correlates with angiogenesis and survival in malignant astrocytoma. Pathol Oncol Res 2008; 14:293-8.
33. Burdo TH, Wood MR, Fox HS. Osteopontin prevents monocyte recirculation and apoptosis. J Leukoc Biol 2007; 81:1504-11.
34. Burdo TH, Ellis RJ, Fox HS. Osteopontin is increased in HIV-associated dementia. J Infect Dis 2008; 198:715-22.
35. Rittling SR, Matsumoto HN, McKee MD et al. Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res 1998; 13:1101-11.
36. Banerjee A, Lee JH, Ramaiah SK. Interaction of osteopontin with neutrophil α4β1 and α9β1 integrins in a rodent model of alcoholic liver disease. Toxicol Appl Pharmacol 2008; 233:238-46.
37. Korkola JE, Houldsworth J, Chadalavada RS, Olshen AB, Dobrzynski D, Reuter VE, Bosl GJ, Chaganti RS. Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vitro differentiation of human male germ cell tumors. Cancer Res 2006; 66:820-7.
38. Varambally S, Yu J, Laxman B et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005; 8:393-406.
39. Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J, Atkins D, Wang Y. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 2005; 11:7234-42.
40. Lapointe J, Li C, Higgins JP et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2004; 101:811-6.
41. Lenburg ME, Liou LS, Gerry NP, Framton GM, Cohen HT, Christman MF. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer 2003; 3:31.
42. Welsh JB, Zarrinkar PP, Sapinoso LM et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A 2001; 98:1176-81.
43. Dehan E, Ben-Dor A, Liao W et al. Chromosomal aberrations and gene expression profiles in non-small cell lung cancer. Lung Cancer 2007; 56:175-84.
44. Wachi S, Yoneda K, Wu R. Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. Bioinformatics 2005; 21:4205-8.
45. Inamura K, Fujiwara T, Hoshida Y et al. Two subclasses of lung squamous cell carcinoma with different gene expression profiles and prognosis identified by hierarchical clustering and non-negative matrix factorization. Oncogene 2005; 24:7105-13.
46. Kimchi ET, Posner MC, Park JO. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res 2005; 65:3146-54.
47. Chen X, Higgins J, Cheung ST et al. Novel endothelial cell markers in hepatocellular carcinoma. Mod Pathol 2004; 17:1198-210.
48. Chung CH, Parker JS, Karaca G et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004; 5:489-500.
49. Quade BJ, Wang TY, Sornberger K, Dal CP, Mutter GL, Morton CC. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling. Genes Chromosomes Cancer 2004; 40:97-108.
50. Jones MH, Virtanen C, Honjoh D et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 2004; 363:775-81.
51. Cromer A, Carles A, Millon R et al. Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. Oncogene 2004; 23:2484-98.
52. Chen X, Leung SY, Yuen ST et al. Variation in gene expression patterns in human gastric cancers. Mol Biol Cell 2003; 14:3208-15.
53. Virtanen C, Ishikawa Y, Honjoh D, Kimura M, Shimane M, Miyoshi T, Nomura H, Jones MH. Integrated classification of lung tumors and cell lines by expression profiling. Proc Natl Acad Sci U S A 2002; 99:12357-62.
54. Beer DG, Kardia SL, Huang CC et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002; 8:816-24.
55. Chen X, Cheung ST, So S et al. Gene expression patterns in human liver cancers. Mol Biol Cell 2002; 13:1929-39.
56. Bhattacharjee A, Richards WG, Staunton J et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001; 98:13790-5.
57. Notterman DA, Alon U, Sierk AJ, Levine AJ. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res 2001; 61:3124-30.
58. Honore S, Lascols C, Malin D, Targaouchi R, Cattoir V, Legrand P, Soussy CJ, Cambau E. Investigation of the new QNR-based mechanism of quinolone resistance among enterobacterial strains isolated in Henri-Mondor hospital 2002-2005. Pathol Biol (Paris) 2006; 54:270-9.
59. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-52.
60. Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Lensen JL, Moller K, Orntoft TF. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 2004; 64:4040-8.
61. Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, Sikic BI. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res 2005; 65:8679-89.
62. Bredel M, Bredel C, Juric D et al. Tumor necrosis factor-α-induced protein 3 as a putative regulator of nuclear factor-κB-mediated resistance to O6-alkylating agents in human glioblastomas. J Clin Oncol 2006; 24:274-87.
63. Kotliarov Y, Steed ME, Christopher N et al. High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic inbalances. Cancer Res 2006; 66:9428-36.
64. Richardson AL, Wang ZC, De NA et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006; 9:121-32.
65. Miccadei S, Provenzano C, Mojzisek M, Natali PG, Civitareale D. Retinoblastoma protein acts as Pax 8 transcriptional coactivator. Oncogene 2005; 24:6993-7001.
66. Kuriakose MA, Chen WT, He ZM et al. Selection and validation of differentially expressed genes in head and neck cancer. Cell Mol Life Sci 2004; 61:1372-83.
67. Iacobuzio-Donahue CA, Maitra A, Olsen M et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 2003; 162:1151-62.
68. Hippo Y, Taniguchi H, Tsutsumi S, Machida N, Chong JM, Fukayama M, Kodama T, Aburatani H. Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res 2002; 62:233-40.
69. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL96.
70. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE5206.
71. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1037.
72. http://www.ncbi.nlm.nih.gov/sites/GDSbrowser?acc=GDS1732.
73. Bronckers AL, Sasaguri K, Engelse MA. Transcription and immunolocalization of Runx2/Cbfa1/Pebp2αA in developing rodent and human craniofacial tissues: further evidence suggesting osteoclasts phagocytose osteocytes. Microsc Res Tech 2003; 61:540-8.
74. Griffini P, Smorenburg SM, Vogels IM, Tigchelaar W, Van Noorden CJ. Kupffer cells and pit cells are not effective in the defense against experimentally induced colon carcinoma metastasis in rat liver. Clin Exp Metastasis 1996; 14:367-80.
75. Chieco P, Jonker A, Van Noorden CJ. Image Cytometry. Oxford: Bios, Royal Microscopical Society Handbooks, 2001.
76. Kellgren JH, Lawrence JS. Radiological assessment of rheumatoid arthritis. Ann Rheum Dis 1957; 16:485-93.
77. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957; 16:494-502.
78. Rijk PC, De Rooy TP, Coerkamp EG, Bernoski FP, Van Noorden CJ. Radiographic evaluation of the knee joint after meniscal allograft transplantation. An experimental study in rabbits. Knee Surg Sports Traumatol Arthrosc 2002; 10:241-6.
79. Bellahcene A, Castronovo V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol 1995; 146:95-100.
80. Guldur ME, Kibar Y, Deniz H, Bakir K. Comparison of osteopontin, beta-catenin and hnRNP B1 expression in lung carcinomas. Pathol Oncol Res 2010; 16:55-9.
81. Park JB, Kwak HJ, Lee SH. Role of hyaluronan in glioma invasion. Cell Adh Migr 2008; 2:202-7.
82. Jin KL, Mao XO, Greenberg DA. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci U S A 2000; 97:10242-7.
83. Nishijima K, Ng YS, Zhong L et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007; 171:53-67.
84. Said HM, Hagemann C, Staab A et al. Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1α in human glioma in vitro and in vitro. Radiother Oncol 2007; 83:398-405.
85. Hughes JM, Groot AJ, Van Der Groep P et al. Active HIF-1 in the normal human retina. J Histochem Cytochem 2010; 58:247-54.
86. Jang T, Savaresse T, Low HP et al. Osteopontin expression in intratumoral astrocytes marks tumor progression in gliomas induced by prenatal exposure to N-ethyl-N-nitrosourea. Am J Pathol 2006; 168:1676-85.
87. Bellail AC, Hunter SB, Brat DJ, Tan C, Van Meir EG. Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol 2004; 36:1046-69.
88. Lafrance JP, Nolin L, Senecal L, Leblanc M. Predictors and outcome of cardiopulmonary resuscitation (CPR) calls in a large haemodialysis unit over a seven-year period. Nephrol Dial Transplant 2006; 21:1006-12.
89. Rangaswami HR, Bulbule A, Kundu GC. Nuclear factor inducing kinase: a key regulator in osteopontin- induced MAPK/IκB kinase dependent NF-κB-mediated promatrix metalloproteinase-9 activation. Glycoconj J 2006; 23:221-32.
90. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003; 3:489-501.
91. Tuck AB, Chambers AF, Allan AL. Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem 2007; 102:859-68.
92. Chen YJ, Wei YY, Chen HT et al. Osteopontin increases migration and MMP-9 up-regulation via αvβ3 integrin, FAK, ERK, and NF-κB-dependent pathway in human chondrosarcoma cells. J Cell Physiol 2009; 221:98-108.
93. Diao H, Kon S, Iwabuchi K et al. Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity 2004; 21:539-50.
94. Diao H, Iwabuchi K, Li L et al. Osteopontin regulates development and function of invariant natural killer T cells. Proc Natl Acad Sci U S A 2008; 105:15884-9.
95. Fong YC, Liu SC, Huang CY et al. Osteopontin increases lung cancer cells migration via activation of the αvβ3 integrin/FAK/Akt and NF-κB-dependent pathway. Lung Cancer 2009; 64:263-70.
96. Ito K, Kon S, Nakayama Y et al. The differential amino acid requirement within osteopontin in α4 and α9 integrin-mediated cell binding and migration. Matrix Biol 2009; 28:11-9.
97. Moon C, Han JR, Park HJ, Hah JS, Kang JL. Synthetic RGDS peptide attenuates lipopolysaccharide-induced pulmonary inflammation by inhibiting integrin signaled MAP kinase pathways. Respir Res 2009; 10:18.
98. Nakamura I, Pilkington MF, Lakkakorpi PT, Lipfert L, Sims SM, Dixon SJ, Rodan GA, Duong LT. Role of αvβ3 integrin in osteoclast migration and formation of the sealing zone. J Cell Sci 1999; 112:3985-93.
99. Nakamura I, Duong LT, Rodan SB, Rodan GA. Involvement of αvβ3 integrins in osteoclast function. J Bone Miner Metab 2007; 25:337-44.
100. Nishimichi N, Higashikawa F, Kinoh HH, Tateishi Y, Matsuda H, Yokosaki Y. Polymeric osteopontin employs integrin α9β1 as a receptor and attracts neutrophils by presenting a de novo binding site. J Biol Chem 2009; 284:14769-76.
101. Smith LL, Giachelli CM. Structural requirements for α9β1-mediated adhesion and migration to thrombin-cleaved osteopontin. Exp Cell Res 1998; 242:351-60.
102. Yokasaki Y, Sheppard D. Mapping of the cryptic integrin-binding site in osteopontin suggests a new mechanism by which thrombin can regulate inflammation and tissue repair. Trends Cardiovasc Med 2000; 10:155-9.
103. Yokosaki Y, Matsuura N, Sasaki T et al. The integrin α9β1 binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem 1999; 274:36328-34.
104. Smorenburg SM, Griffini P, Tiggelman AB, Moorman AF, Boers W, Van Noorden CJ. α2-Macroglobulin is mainly produced by cancer cells and not by hepatocytes in rats with colon carcinoma metastases in liver. Hepatology 1996; 23:560-70.